CL2020002881A1 - Uso de canakinumab - Google Patents
Uso de canakinumabInfo
- Publication number
- CL2020002881A1 CL2020002881A1 CL2020002881A CL2020002881A CL2020002881A1 CL 2020002881 A1 CL2020002881 A1 CL 2020002881A1 CL 2020002881 A CL2020002881 A CL 2020002881A CL 2020002881 A CL2020002881 A CL 2020002881A CL 2020002881 A1 CL2020002881 A1 CL 2020002881A1
- Authority
- CL
- Chile
- Prior art keywords
- canakinumab
- osteoarthritis
- inhibitor
- prevention
- treatment
- Prior art date
Links
- 229960001838 canakinumab Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un inhibidor de IL–1ß, tal como canakinumab, para el tratamiento y/o la prevención de la artrosis y de complicaciones relacionadas con ella.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862669071P | 2018-05-09 | 2018-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002881A1 true CL2020002881A1 (es) | 2021-05-14 |
Family
ID=63638190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002881A CL2020002881A1 (es) | 2018-05-09 | 2020-11-06 | Uso de canakinumab |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210371511A1 (es) |
EP (1) | EP3790576A1 (es) |
JP (2) | JP2021523894A (es) |
KR (1) | KR20210008847A (es) |
CN (1) | CN112584857A (es) |
AU (1) | AU2018422406A1 (es) |
BR (1) | BR112020022576A2 (es) |
CA (1) | CA3098277A1 (es) |
CL (1) | CL2020002881A1 (es) |
MX (1) | MX2020011909A (es) |
TW (1) | TW201946652A (es) |
WO (1) | WO2019215484A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
EP3332807B1 (en) | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
CN104800844A (zh) * | 2010-11-05 | 2015-07-29 | 诺华有限公司 | 使用il-17拮抗剂治疗类风湿性关节炎的方法 |
AR088083A1 (es) | 2011-09-30 | 2014-05-07 | Novartis Ag | USO DE ANTICUERPOS DE UNION A IL-1b |
JP2016540761A (ja) * | 2013-12-02 | 2016-12-28 | アッヴィ・インコーポレイテッド | 変形性関節症を治療するための組成物及び方法 |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
JP2020524694A (ja) * | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのIL−1β結合性抗体 |
CN107723310B (zh) * | 2017-10-19 | 2024-01-09 | 北京睿诚海汇健康科技有限公司 | 植物作为宿主在表达卡那抗体中的应用 |
-
2018
- 2018-08-24 CA CA3098277A patent/CA3098277A1/en not_active Abandoned
- 2018-08-24 EP EP18772905.8A patent/EP3790576A1/en active Pending
- 2018-08-24 WO PCT/IB2018/056455 patent/WO2019215484A1/en unknown
- 2018-08-24 MX MX2020011909A patent/MX2020011909A/es unknown
- 2018-08-24 US US17/053,602 patent/US20210371511A1/en active Pending
- 2018-08-24 JP JP2020562124A patent/JP2021523894A/ja not_active Withdrawn
- 2018-08-24 TW TW107129705A patent/TW201946652A/zh unknown
- 2018-08-24 CN CN201880094285.6A patent/CN112584857A/zh active Pending
- 2018-08-24 BR BR112020022576-2A patent/BR112020022576A2/pt not_active IP Right Cessation
- 2018-08-24 AU AU2018422406A patent/AU2018422406A1/en not_active Abandoned
- 2018-08-24 KR KR1020207035003A patent/KR20210008847A/ko not_active Application Discontinuation
-
2020
- 2020-11-06 CL CL2020002881A patent/CL2020002881A1/es unknown
-
2023
- 2023-03-07 JP JP2023034283A patent/JP2023071904A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3790576A1 (en) | 2021-03-17 |
AU2018422406A1 (en) | 2020-11-12 |
CA3098277A1 (en) | 2019-11-14 |
JP2023071904A (ja) | 2023-05-23 |
JP2021523894A (ja) | 2021-09-09 |
MX2020011909A (es) | 2021-01-29 |
BR112020022576A2 (pt) | 2021-02-09 |
CN112584857A (zh) | 2021-03-30 |
US20210371511A1 (en) | 2021-12-02 |
KR20210008847A (ko) | 2021-01-25 |
TW201946652A (zh) | 2019-12-16 |
WO2019215484A1 (en) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
MX2020001103A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
MX2018002217A (es) | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
CL2020003083A1 (es) | Inhibidores de masp-2 y métodos de uso | |
CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
CL2017002765A1 (es) | El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc). | |
EA202092692A1 (ru) | Аналоги рапамицина и их применения | |
EP4234552A3 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
MX2019010643A (es) | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). | |
MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF |